Skip to main content

Real-World Outcomes After Dupilumab Initiation for Pediatric Chronic Rhinosinusitis with Nasal Polyps

In brief

Dupilumab was linked to half as many sinus surgeries in children

Among 442 matched children with chronic sinusitis and nasal polyps, those starting dupilumab had fewer sinus surgeries over 12 months than controls: 8.6% versus 17.2%. Acute sinusitis and steroid bursts were also less frequent, while emergency visits and hospital admissions were similar. Because this was a retrospective study, it cannot show that dupilumab caused the differences.

Journal
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (Q1)
Published
17 November 2026
Study design
Retrospective cohort
Evidence level
Level 3, Low (CEBM 3b)
Authors
Maaz S Haji, Abraham A Kassem, Alexa F Ibrahim, Paula V G Navarro, Deepthi Akella, Michele M Carr
PMID
43042972
DOI
10.1002/ohn.70523

Why clinicians should know about it

  • Picked for Immunology and Allergy (paper of the day, 19 November 2026): Real-world dupilumab outcomes for pediatric nasal polyposis

Abstract

OBJECTIVE: To evaluate whether dupilumab initiation is associated with reduced short-term flare burden, healthcare utilization, and surgical escalation in pediatric patients with chronic rhinosinusitis with nasal polyps (CRSwNP). STUDY DESIGN: Retrospective cohort study. SETTING: TriNetX United States Collaborative Network. METHODS: Patients aged ≤18 years with chronic rhinosinusitis with nasal polyps were identified between January 1, 2015, and December 31, 2024. Dupilumab-treated patients were indexed at treatment initiation and propensity score-matched 1:1 to nondupilumab controls indexed at a systemic corticosteroid burst based on asthma, atopic dermatitis, allergic rhinitis, and prior endoscopic sinus surgery. Outcomes within 12 months were compared using risk ratios. RESULTS: In 442 matched patients (221 per cohort), dupilumab-treated patients had lower rates of acute sinusitis (12/221 [5.4%] vs 31/221 [14.0%]; risk ratio [RR] 0.39; 95% CI: 0.20-0.73; P = .002), systemic corticosteroid bursts (80/221 [36.2%] vs 101/221 [45.7%]; RR 0.79; 95% CI: 0.63-0.99; P = .042), and functional endoscopic sinus surgery (19/221 [8.6%] vs 38/221 [17.2%]; RR 0.50; 95% CI: 0.30-0.84; P = .007). Nasal polyp diagnoses were more frequently documented in the dupilumab-treated cohort (148/221 [67.0%] vs 95/221 [43.0%]; P < .0001), while emergency department visits (16/221 [7.2%] vs 27/221 [12.2%]; P = .078) and inpatient admissions (12/221 [5.4%] vs 16/221 [7.2%]; P = .435) were similar between cohorts. CONCLUSION: These findings suggest that dupilumab may be a steroid-sparing and surgery-sparing option in pediatric CRSwNP.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.